Magnani L - Search Results

1

Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.

Bhat-Nakshatri P, Goswami CP, Badve S, Magnani L, Lupien M, Nakshatri H. Bhat-Nakshatri P, et al. Among authors: magnani l. Cancer Res. 2016 Jul 1;76(13):3989-4001. doi: 10.1158/0008-5472.CAN-15-3174. Epub 2016 Apr 25. Cancer Res. 2016. PMID: 27197157 Free article.

2

Pioneer factors: directing transcriptional regulators within the chromatin environment.

Magnani L, Eeckhoute J, Lupien M. Magnani L, et al. Trends Genet. 2011 Nov;27(11):465-74. doi: 10.1016/j.tig.2011.07.002. Epub 2011 Aug 30. Trends Genet. 2011. PMID: 21885149 Review.

3

PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.

Magnani L, Ballantyne EB, Zhang X, Lupien M. Magnani L, et al. PLoS Genet. 2011 Nov;7(11):e1002368. doi: 10.1371/journal.pgen.1002368. Epub 2011 Nov 17. PLoS Genet. 2011. PMID: 22125492 Free PMC article.

4

Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites.

Thiaville MM, Stoeck A, Chen L, Wu RC, Magnani L, Oidtman J, Shih IeM, Lupien M, Wang TL. Thiaville MM, et al. Among authors: magnani l. PLoS One. 2012;7(5):e36054. doi: 10.1371/journal.pone.0036054. Epub 2012 May 2. PLoS One. 2012. PMID: 22567123 Free PMC article.

5

Chromatin landscape and endocrine response in breast cancer.

Magnani L, Brunelle M, Gévry N, Lupien M. Magnani L, et al. Epigenomics. 2012 Dec;4(6):675-83. doi: 10.2217/epi.12.64. Epigenomics. 2012. PMID: 23244312 Review.

6

Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.

Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang TL, Gyorffy B, Lupien M. Magnani L, et al. Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):E1490-9. doi: 10.1073/pnas.1219992110. Epub 2013 Apr 1. Proc Natl Acad Sci U S A. 2013. PMID: 23576735 Free PMC article.

7

Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling.

Magnani L, Lupien M. Magnani L, et al. Mol Cell Endocrinol. 2014 Jan 25;382(1):633-641. doi: 10.1016/j.mce.2013.04.026. Epub 2013 May 16. Mol Cell Endocrinol. 2014. PMID: 23684889 Review.

8

LRH-1 governs vital transcriptional programs in endocrine-sensitive and -resistant breast cancer cells.

Bianco S, Brunelle M, Jangal M, Magnani L, Gévry N. Bianco S, et al. Among authors: magnani l. Cancer Res. 2014 Apr 1;74(7):2015-25. doi: 10.1158/0008-5472.CAN-13-2351. Epub 2014 Feb 11. Cancer Res. 2014. PMID: 24520076

9

DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation.

Faronato M, Nguyen VT, Patten DK, Lombardo Y, Steel JH, Patel N, Woodley L, Shousha S, Pruneri G, Coombes RC, Magnani L. Faronato M, et al. Among authors: magnani l. Oncotarget. 2015 Sep 8;6(26):22467-79. doi: 10.18632/oncotarget.4164. Oncotarget. 2015. PMID: 26093085 Free PMC article.

10

The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.

Magnani L, Patten DK, Nguyen VT, Hong SP, Steel JH, Patel N, Lombardo Y, Faronato M, Gomes AR, Woodley L, Page K, Guttery D, Primrose L, Fernandez Garcia D, Shaw J, Viola P, Green A, Nolan C, Ellis IO, Rakha EA, Shousha S, Lam EW, Győrffy B, Lupien M, Coombes RC. Magnani L, et al. Oncotarget. 2015 Sep 8;6(26):21878-91. doi: 10.18632/oncotarget.4243. Oncotarget. 2015. PMID: 26215677 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters